Evaluation of methods for testing the susceptibility of clinical mycobacterium tuberculosis isolates to pyrazinamide

Journal of Clinical Microbiology

Volumn 51, Issue 5, 2013, Pages 1374-1380

  Cui, Zhenling ^a   Wang, Jie ^a   Lu, Junmei ^a   Huang, Xiaochen ^a   Zheng, Ruijuan ^a   Hu, Zhongyi ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BACTERIAL ENZYME; GENOMIC DNA; PYRAZINAMIDASE; PYRAZINAMIDE; RESAZURIN; UNCLASSIFIED DRUG; AMIDASE; OXAZINE DERIVATIVE; PNCA PROTEIN, MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE DEAMIDASE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TUBERCULOSTATIC AGENT; XANTHENE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; COLORIMETRY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; DNA EXTRACTION; ENZYME ACTIVITY; GENE SEQUENCE; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; MTT REDUCTION TEST; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PNCA GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; RESAZURIN MICROTITER ASSAY; SENSITIVITY AND SPECIFICITY; DRUG EFFECTS; EVALUATION STUDY; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; PROCEDURES;

MYCOBACTERIUM TUBERCULOSIS;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXAZINES; PYRAZINAMIDE; TETRAZOLIUM SALTS; THIAZOLES; XANTHENES;

EID: 84876770844     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03197-12     Document Type: Article

References (36)

1. World Health Organization. 2010. Treatment of tuberculosis: guidelines for national programmes, 4th ed. WHO/HTM/TB/2009.420. World Health Organization, Geneva, Switzerland.
2. Mitchison DA. 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219-225.
3. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. 2003. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52:790-795.
4. Tarshis MS, Jr, Weed WA. 1953. Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am. Rev. Tuberc. 67:391-395.
5. Salfinger M, Heifets LB. 1988. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob. Agents Chemother. 32:1002-1004.
6. World Health Organization. 2009. Guidelines for surveillance of drug resistance in tuberculosis, 4th ed. WHO/HTM/TB/2009.422. World Health Organization, Geneva, Switzerland.
7. Denkin S, Volokhov D, Chizhikov V, Zhang Y. 2005. Microarray-based pncA genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis. J. Med. Microbiol. 54:1127-1131.
8. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. 2011. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:2032-2041.
9. Miller MA, Thibert L, Desjardins F, Siddiqi SH, Dascal A. 1995. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay. J. Clin. Microbiol. 33: 2468-2470.
10. Singh P, Wesley C, Jadaun GP, Malonia SK, Das R, Upadhyay P, Faujdar J, Sharma P, Gupta P, Mishra AK, Singh K, Chauhan DS, Sharma VD, Gupta UD, Venkatesan K, Katoch VM. 2007. Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 45:76-80.
11. Leite CQ, Beretta AL, Anno IS, Telles MA. 2000. Standardization of broth microdilution method for Mycobacterium tuberculosis. Mem. Inst. Oswaldo Cruz 95:127-129.
12. Syre H, Øvreås K, Grewal HM. 2010. Determination of the susceptibility of Mycobacterium tuberculosis to pyrazinamide in liquid and solid media assessed by a colorimetric nitrate reductase assay. J. Antimicrob. Chemother. 65:704-712.
13. Thierry D, Cave MD, Eisenach KD, Crawford JT, Bates JH, Gicquel B, Guesdon JL. 1990. IS6110, an IS-like element of Mycobacterium tuberculosis complex. Nucleic Acids Res. 18:188. doi:10.1093/nar/18.1.188.
14. Barouni AS, Augusto CJ, Lopes MT, Zanini MS, Salas CE. 2004. A pncA polymorphism to differentiate between Mycobacterium bovis and Mycobacterium tuberculosis. Mol. Cell. Probes 18:167-170.
15. Kontos F, Nicolaou S, Kostopoulos C, Gitti Z, Petinaki E, Maniati M, Anagnostou S, Raftopoulou A, Papageorgiou P, Scrioubellou A, Tselentis I, Maniatis AN. 2003. Multicenter evaluation of the fully automated Bactec MGIT 960 system for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide: comparison with the radiometric Bactec 460TB system. J. Microbiol. Methods 55:331-333.
16. Pfyffer GE, Palicova F, Rüsch-Gerdes S. 2002. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system. J. Clin. Microbiol. 40:1670-1674.
17. Cui Z, Wang J, Lu J, Huang X, Hu Z. 2011. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infect. Dis. 11:78. doi: 10.1186/1471-2334-11-78.
18. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, III, Wang H, Zhang W, Zhang Y. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632.
19. Wayne LG. 1974. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am. Rev. Respir. Dis. 109:147-151.
20. Morlock GP, Crawford JT, Butler WR, Brim SE, Sikes D, Mazurek GH, Woodley CL, Cooksey RC. 2000. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:2291-2295.
21. Rivoire N, Ravololonandriana P, Rasolonavalona T, Martin A, Portaels F, Ramarokoto H, Rasolofo Razanamparany V. 2007. Evaluation of the resazurin assay for the detection of multidrug-resistant Mycobacterium tuberculosis in Madagascar. Int. J. Tuberc. Lung Dis. 11:683-688.
22. CLSI. 2011. Susceptibility testing of mycobacteria, Nocardiae, and other aerobic actinonycetes; approved standard, 2nd ed. CLSI M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Mshana RN, Tadesse G, Abate G, Miörner H. 1998. Use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide for rapid detection of rifampin-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 36:1214-1219.
24. Iseman MD. 1993. Treatment of multidrug-resistant tuberculosis. N. Engl. J. Med. 329:784-791.
25. Chaulet P, Boulahbal F, Grosset J. 1995. Surveillance of drug resistance for tuberculosis control: why and how? Tuber. Lung Dis. 76:487-492.
26. World Health Organization. 1994. World Health Organization Tuberculosis Programme and International Union Against Tuberculosis and Lung Disease guidelines for surveillance of drug resistance in tuberculosis. WHO/TB/94.178. World Health Organization, Geneva, Switzerland.
27. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. 2010. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 48:300-301.
28. Piersimoni C, Mustazzolu A, Giannoni F, Bornigia S, Gherardi G, Fattorini L. 2013. Prevention of false resistance results obtained testing susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum. J. Clin. Microbiol. 51: 291-294.
29. Werngren J, Sturegård E, Juréen P, Angeby K, Hoffner S, Schön T. 2012. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wildtype MIC distributions and pncA gene sequencing. Antimicrob. Agents Chemother. 56:1253-1257.
30. Heifets LB, Flory MA, Lindholm-Levy PJ. 1989. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis? Antimicrob. Agents Chemother. 33:1252-1254.
31. Sun Z, Scorpio A, Zhang Y. 1997. The pncA gene from naturally pyrazinamide-resistant Mycobacterium avium encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant M. tuberculosis complex organisms. Microbiology 143:3367-3373.
32. Sharma B, Pal N, Malhotra B, Vyas L, Rishi S. 2010. Comparison of MGIT 960&pyrazinamidase activity assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. Indian J. Med. Res. 132:72-76.
33. Butler WR, Kilburn JO. 1983. Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity. Antimicrob. Agents Chemother. 24:600-601.
34. Zhou M, Geng X, Chen J, Wang X, Wang D, Deng J, Zhang Z, Wang W, Zhang XE, Wei H. 2011. Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method. PLoS One 6:e27654. doi:10.1371/journal.pone .0027654.
35. Quiliano M, Gutierrez AH, Gilman RH, López C, Evangelista W, Sotelo J, Sheen P, Zimic M. 2011. Structure-activity relationship in mutated pyrazinamidases from Mycobacterium tuberculosis. Bioinformation 6:335-339.
36. Petrella S, Gelus-Ziental N, Maudry A, Laurans C, Boudjelloul R, Sougakoff W. 2011. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide. PLoS One 6:e15785. doi:10.1371/journal.pone.0015785.